Telephone-Based Support Programs for People With Epilepsy and Depression
This study is testing two telephone-based support programs for people with epilepsy (a brain disorder that causes seizures) who also experience symptoms of depression. One program, UPLIFT, combines cognitive behavioral therapy (CBT) and mindfulness. The other, BOOST, is a group discussion-based support program. Both programs last 8 weeks, with weekly one-hour phone sessions in small groups. The study aims to see if these programs can reduce depressive symptoms and improve quality of life and seizure control over 12 months. You might be able to join if you are an adult (18-99 years old) with epilepsy for at least a year, speak English or Spanish, and have elevated depressive symptoms.
- Study design
- This is a randomized controlled trial comparing two telephone-based programs, UPLIFT and BOOST, with 120 participants.
- What's involved
- You would participate in 8 weekly one-hour group telephone sessions. Your depressive symptoms will be measured at the beginning, 3 months, and 6 months.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your depressive symptoms, quality of life, and seizures will be assessed over 12 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Telephone-Based Support Programs for People With Epilepsy
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Daniel Friedman, MD · PRINCIPAL_INVESTIGATOR · NYU Langone Health
- Tanya Spruill, PhD · PRINCIPAL_INVESTIGATOR · NYU Langone Health
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Presence of clinically significant depressive symptomsBaseline Visit
The primary outcome is a dichotomous measure of depressive symptoms based on a Patient Health Questionnaire (PHQ-9) score of \<5 versus ≥5. The PHQ-9 assesses depressive symptoms in the past two weeks. Total scores range from 0-27 with recommended cutoffs for mild (5-9), moderate (10-14), moderately severe (15-19) and severe (≥20) depressive symptoms. A PHQ-9 score of \<5 indicates absence of clinically significant depressive symptoms.
- Presence of clinically significant depressive symptoms3 month visit
The primary outcome is a dichotomous measure of depressive symptoms based on a Patient Health Questionnaire (PHQ-9) score of \<5 versus ≥5. The PHQ-9 assesses depressive symptoms in the past two weeks. Total scores range from 0-27 with recommended cutoffs for mild (5-9), moderate (10-14), moderately severe (15-19) and severe (≥20) depressive symptoms. A PHQ-9 score of \<5 indicates absence of clinically significant depressive symptoms.
- Presence of clinically significant depressive symptoms6 month visit
The primary outcome is a dichotomous measure of depressive symptoms based on a Patient Health Questionnaire (PHQ-9) score of \<5 versus ≥5. The PHQ-9 assesses depressive symptoms in the past two weeks. Total scores range from 0-27 with recommended cutoffs for mild (5-9), moderate (10-14), moderately severe (15-19) and severe (≥20) depressive symptoms. A PHQ-9 score of \<5 indicates absence of clinically significant depressive symptoms.
- Presence of clinically significant depressive symptoms12 month visit
The primary outcome is a dichotomous measure of depressive symptoms based on a Patient Health Questionnaire (PHQ-9) score of \<5 versus ≥5. The PHQ-9 assesses depressive symptoms in the past two weeks. Total scores range from 0-27 with recommended cutoffs for mild (5-9), moderate (10-14), moderately severe (15-19) and severe (≥20) depressive symptoms. A PHQ-9 score of \<5 indicates absence of clinically significant depressive symptoms.